These findings suggested that omentin is selectively amplified in gastrointestinal cancer—particularly when cachexia is present—implicating it as a candidate mediator of fat–muscle cross-talk and a potential therapeutic target in cancer-associated metabolic dysfunction [42]. Here, ITLN1 is linked to cancer.